SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Oncolytics Biotech Doses First Patient In Phase 2 IRENE Study Evaluating Pelareorep-Anti-PD-1 Combination Treatment In Triple-Negative Breast Cancer

  - Expansion of Oncolytics' lead breast cancer program into a new disease subtype - Seek synergies between pelareorep and retifanlimab checkpoint inhibitor SAN DIEGO, Calif. and CALGARY, Alberta, Aug. 26,

Benzinga · 08/26/2020 11:13

 

- Expansion of Oncolytics' lead breast cancer program into a new disease subtype

- Seek synergies between pelareorep and retifanlimab checkpoint inhibitor

SAN DIEGO, Calif. and CALGARY, Alberta, Aug. 26, 2020 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The study, known as IRENE, is co-sponsored by Oncolytics, the Rutgers Cancer Institute of New Jersey, and Incyte. Participants in the multi-center study receive pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012).